Nasdaq:US$13.02 (-0.38) | HKEX:HK$20.65 (-0.65) | AIM:£2.20 (+0.03)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 6 Apr 2013

AACR 2013: Synergistic effect of c-Met inhibitor savolitinib in combination with EGFR inhibitor Gefitinib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquired Met gene amplification